GB1390772A - Oral narcotic composition - Google Patents
Oral narcotic compositionInfo
- Publication number
- GB1390772A GB1390772A GB1131972A GB1131972A GB1390772A GB 1390772 A GB1390772 A GB 1390772A GB 1131972 A GB1131972 A GB 1131972A GB 1131972 A GB1131972 A GB 1131972A GB 1390772 A GB1390772 A GB 1390772A
- Authority
- GB
- United Kingdom
- Prior art keywords
- narcotic
- salts
- composition
- orally
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000003533 narcotic effect Effects 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000002921 anti-spasmodic effect Effects 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229940124575 antispasmodic agent Drugs 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- 229960004126 codeine Drugs 0.000 abstract 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 abstract 1
- 229960004193 dextropropoxyphene Drugs 0.000 abstract 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002743 euphoric effect Effects 0.000 abstract 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 abstract 1
- 229960000240 hydrocodone Drugs 0.000 abstract 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 abstract 1
- 229960004127 naloxone Drugs 0.000 abstract 1
- 239000003887 narcotic antagonist Substances 0.000 abstract 1
- 229960002085 oxycodone Drugs 0.000 abstract 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 abstract 1
- 229960005301 pentazocine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960003893 phenacetin Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14140771A | 1971-05-07 | 1971-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1390772A true GB1390772A (en) | 1975-04-16 |
Family
ID=22495561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1131972A Expired GB1390772A (en) | 1971-05-07 | 1972-03-10 | Oral narcotic composition |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2222039A1 (enExample) |
| FR (1) | FR2137560B1 (enExample) |
| GB (1) | GB1390772A (enExample) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0900582A1 (en) * | 1997-08-21 | 1999-03-10 | Johnson Matthey Public Limited Company | Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals |
| WO2003007802A3 (en) * | 2001-07-18 | 2003-11-27 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
| WO2003084520A3 (en) * | 2002-04-05 | 2004-03-11 | Euro Celtique Sa | Pharmaceutical preparation containing oxycodone and naloxone |
| EP1299104A4 (en) * | 2000-02-08 | 2004-04-21 | Euro Celtique Sa | MISSING SAFE ORAL OPIOID AGONIST PREPARATIONS |
| EP1810678A1 (de) * | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
| US8465774B2 (en) | 2001-08-06 | 2013-06-18 | Purdue Pharma L.P. | Sequestered antagonist formulations |
| US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
| US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| US9101625B2 (en) | 2006-08-30 | 2015-08-11 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
| US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| AU2402392A (en) * | 1991-08-06 | 1993-03-02 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New anti-diarrheic agents |
| FR2681922B1 (fr) * | 1991-09-30 | 1993-11-26 | Bendix Europe Services Technique | Organe de friction muni d'un dispositif indicateur d'usure et frein a disque equipe d'un tel organe. |
| CN1204890C (zh) | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US7914818B2 (en) | 2001-08-06 | 2011-03-29 | Purdue Pharma L.P. | Opioid agonist formulations with releasable and sequestered antagonist |
| EP2422773A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
| MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
| ES2636657T3 (es) | 2006-06-19 | 2017-10-06 | Alpharma Pharmaceuticals Llc | Composición farmacéutica |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
-
1972
- 1972-03-10 GB GB1131972A patent/GB1390772A/en not_active Expired
- 1972-05-05 FR FR7216146A patent/FR2137560B1/fr not_active Expired
- 1972-05-05 DE DE19722222039 patent/DE2222039A1/de active Pending
Cited By (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981751A (en) * | 1997-08-12 | 1999-11-09 | Johnson Matthey Public Limited Company | Method for removal of residual organic solvents and use thereof in manufacturing pharmaceuticals |
| EP0900582A1 (en) * | 1997-08-21 | 1999-03-10 | Johnson Matthey Public Limited Company | Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals |
| US9205082B2 (en) | 1997-12-22 | 2015-12-08 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US8932630B1 (en) | 1997-12-22 | 2015-01-13 | Purdue Pharma L.P | Opioid agonist/antagonist combinations |
| US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
| US8586088B2 (en) | 2000-02-08 | 2013-11-19 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US7718192B2 (en) * | 2000-02-08 | 2010-05-18 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US10588865B2 (en) | 2000-02-08 | 2020-03-17 | Purdue Pharma L.P. | Tamper resistant oral opioid agonist formulations |
| US10350173B2 (en) | 2000-02-08 | 2019-07-16 | Purdue Pharma L.P. | Tamper resistant oral opioid agonist formulations |
| EP1299104A4 (en) * | 2000-02-08 | 2004-04-21 | Euro Celtique Sa | MISSING SAFE ORAL OPIOID AGONIST PREPARATIONS |
| AP1665A (en) * | 2000-02-08 | 2006-09-22 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations. |
| US9801828B2 (en) | 2000-02-08 | 2017-10-31 | Purdue Pharma L.P. | Tamper resistant oral opioid agonist formulations |
| CZ299991B6 (cs) * | 2000-02-08 | 2009-01-14 | Euro-Celtique S.A. | Léková forma |
| CN100563656C (zh) * | 2000-02-08 | 2009-12-02 | 欧罗赛铁克股份有限公司 | 抗破坏口服阿片样激动剂 |
| US7658939B2 (en) | 2000-02-08 | 2010-02-09 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US7682632B2 (en) | 2000-02-08 | 2010-03-23 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US8936812B2 (en) | 2000-02-08 | 2015-01-20 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US9456989B2 (en) | 2000-02-08 | 2016-10-04 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US7842309B2 (en) | 2000-02-08 | 2010-11-30 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US7842311B2 (en) | 2000-02-08 | 2010-11-30 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US9278073B2 (en) | 2000-02-08 | 2016-03-08 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US8357399B2 (en) | 2000-02-08 | 2013-01-22 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US8236351B2 (en) | 2000-02-08 | 2012-08-07 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
| US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
| WO2003007802A3 (en) * | 2001-07-18 | 2003-11-27 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
| AU2002316738B2 (en) * | 2001-07-18 | 2009-01-08 | Euro-Celtique S.A. | Pharmaceutical combinations of oxycodone and naloxone |
| US8465774B2 (en) | 2001-08-06 | 2013-06-18 | Purdue Pharma L.P. | Sequestered antagonist formulations |
| US8758825B2 (en) | 2001-08-06 | 2014-06-24 | Purdue Pharma L.P. | Sequestered antagonist formulations |
| JP2010180233A (ja) * | 2002-04-05 | 2010-08-19 | Euro-Celtique Sa | オキシコドン及びナロキソンを含有する医薬製剤 |
| EP2425825B1 (en) | 2002-04-05 | 2016-11-16 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
| RU2297225C2 (ru) * | 2002-04-05 | 2007-04-20 | Еуро-Селтик С.А. | Матрица, обеспечивающая пролонгированное, инвариантное и независимое высвобождение активных соединений |
| AU2003224040B2 (en) * | 2002-04-05 | 2006-06-22 | Mundipharma Pty Limited | Pharmaceutical preparation containing oxycodone and naloxone |
| US8846091B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
| WO2003084520A3 (en) * | 2002-04-05 | 2004-03-11 | Euro Celtique Sa | Pharmaceutical preparation containing oxycodone and naloxone |
| US10420762B2 (en) | 2002-04-05 | 2019-09-24 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
| CN1646102B (zh) * | 2002-04-05 | 2012-08-15 | 欧洲凯尔蒂克公司 | 含有羟氢可待酮和烯丙羟吗啡酮的药物制剂 |
| EP1492505B1 (en) | 2002-04-05 | 2015-06-03 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
| US9907793B2 (en) | 2002-04-05 | 2018-03-06 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
| JP4755810B2 (ja) * | 2002-04-05 | 2011-08-24 | ユーロ−セルティーク エス．エイ． | オキシコドン及びナロキソンを含有する医薬製剤 |
| RU2342935C2 (ru) * | 2002-04-05 | 2009-01-10 | Еуро-Селтик С.А. | Фармацевтическая композиция для лечения вызываемых опиоидами побочных эффектов и идиопатических синдромов |
| US9655855B2 (en) | 2002-04-05 | 2017-05-23 | Purdue Pharma L.P. | Matrix for sustained, invariant and independent release of active compounds |
| US9555000B2 (en) | 2002-04-05 | 2017-01-31 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
| US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
| RU2295344C2 (ru) * | 2002-04-05 | 2007-03-20 | Еуро-Селтик С.А. | Фармацевтический препарат, содержащий оксикодон и налоксон |
| US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
| US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
| EA014539B1 (ru) * | 2006-01-19 | 2010-12-30 | Фенукс Аг | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов |
| US10507205B2 (en) | 2006-01-19 | 2019-12-17 | Purdue Pharmaceutical Products L.P. | Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts |
| WO2007082935A1 (de) * | 2006-01-19 | 2007-07-26 | Phoenux Ag | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen |
| EP1810678A1 (de) * | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
| US9101625B2 (en) | 2006-08-30 | 2015-08-11 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
| US9370512B2 (en) | 2006-08-30 | 2016-06-21 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
| US9861628B2 (en) | 2006-08-30 | 2018-01-09 | Rhodes Pharmaceuticals L.P. | Buprenorphine-wafer for drug substitution therapy |
| US9763931B2 (en) | 2006-08-30 | 2017-09-19 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
| US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US9820983B2 (en) | 2009-03-10 | 2017-11-21 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2137560B1 (enExample) | 1975-10-31 |
| DE2222039A1 (de) | 1972-11-23 |
| FR2137560A1 (enExample) | 1972-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1390772A (en) | Oral narcotic composition | |
| GB1517480A (en) | Opiate analgesic formulation with a low potential for abuse | |
| FI905718A0 (fi) | Transdermalt medel. | |
| NZ177159A (en) | Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions | |
| IE33269L (en) | Pyridobenzodiazepines. | |
| IE45439L (en) | Penicillanic acid derivatives | |
| GB841697A (en) | Analgesic compositions | |
| IE35517B1 (en) | Azepine derivatives | |
| GB1183403A (en) | Antitussive Medicament with Prolonged Effect | |
| WO1991018606A3 (en) | Orally active nonaddicting analgesics | |
| JPS5781409A (en) | External plaster | |
| GB1463505A (en) | Pharmaceutical compositions | |
| GB1442159A (en) | Pharmaceutical compositions containing paracetamol | |
| GB1349138A (en) | Quinazoline derivative | |
| GB1507643A (en) | 4-(5-nitro-2-furyl)quinaldinic acid n-oxide and its use in the treatment of bovine mastitis | |
| GB791644A (en) | Barbiturate pharmaceutical preparations | |
| US3800041A (en) | Analgesic compositions and methods | |
| US3795736A (en) | 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent | |
| RU2083202C1 (ru) | Препарат для анальгезии | |
| GB1254057A (en) | Improvements in or relating to therapeutical composition containing vincamine | |
| GB894609A (en) | Tannates of morphine alkaloids | |
| GB1375806A (enExample) | ||
| GB1261454A (en) | Improved analgesic systems and compositions | |
| GB1340535A (en) | Benzodiazepine derivatives | |
| GB1320069A (en) | 1-methyl-4-piperidyl exo 2-phenylbicyclo 2,2,1 heptane-2- carboxylate and the salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PLNP | Patent lapsed through nonpayment of renewal fees | ||
| 49R | Reference inserted (sect. 9/1949) | ||
| SP | Amendment (slips) printed |